18 research outputs found
CONSORT 2010 flow diagram.
<p>CHC patients who were enrolled and followed up. 93 patients were screened for participation in the study. 13 patients were excluded. 80 patients were randomly assigned to receive a placebo or vitamin D supplements and followed up after six weeks of supplements. BMJ 2010;340:c869. doi:<a href="http://dx.doi.org/10.1136/bmj.c869" target="_blank">10.1136/bmj.c869</a>.</p
Comparing changes in serum levels (or delta) of each parameter in placebo and vitamin D groups during 6-week period of supplement.
<p>Comparing changes in serum levels (or delta) of each parameter in placebo and vitamin D groups during 6-week period of supplement.</p
Mean changes of vitamin D levels.
<p>(A), IP-10 (B) and DPP IV (C) levels after 6-week supplements in placebo and vitamin D groups were demonstrated. The x-axis of each graph represents mean changes of the levels (delta). The blue and orange boxes represent placebo group and vitamin D group, respectively.</p
Baseline characteristics of CHC patients in the placebo and vitamin D groups.
<p>Baseline characteristics of CHC patients in the placebo and vitamin D groups.</p
Comparing mean serum levels of each parameter between pre-and post-supplements in placebo and vitamin D groups.
<p>Comparing mean serum levels of each parameter between pre-and post-supplements in placebo and vitamin D groups.</p
Scatter plot of post treatment VD levels (x-axis) and post treatment IP-10 level (y-axis) including fit line and regression equation were demonstrated.
<p>Scatter plot of post treatment VD levels (x-axis) and post treatment IP-10 level (y-axis) including fit line and regression equation were demonstrated.</p
Correlation of soluble DPP IV and polymorphism of <i>DPP4</i> rs13015258 A>C in patients with chronic hepatitis C genotype 1 infection treated with PEG-IFN-α and ribavirin. Statistics analysis using two-tailed Mann-Whitney U-test.
<p>Correlation of soluble DPP IV and polymorphism of <i>DPP4</i> rs13015258 A>C in patients with chronic hepatitis C genotype 1 infection treated with PEG-IFN-α and ribavirin. Statistics analysis using two-tailed Mann-Whitney U-test.</p
Baseline characteristic of patients with CHC infection.
<p>Abbreviation: AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase.</p><p>Baseline characteristic of patients with CHC infection.</p
Association of <i>CXCL10</i> rs56061981 polymorphism and treatment response in CHC-infected patients who had <i>IL28B</i> CT/TT and CC genotypes.
<p>Association of <i>CXCL10</i> rs56061981 polymorphism and treatment response in CHC-infected patients who had <i>IL28B</i> CT/TT and CC genotypes.</p
Additional file 2: Table S2. of Vitamin D-related gene polymorphism predict treatment response to pegylated interferon-based therapy in Thai chronic hepatitis C patients
Sustained virologic response in relationship with GC, CYP2R1, CYP27B1 and DHCR7 in chronic hepatitis C patients treated with PEG-IFN-Îą based regimen. (DOC 59 kb